BSX Stock Report
2-Year Price History
Recent Price
(7/2 4:16PM)
-2.5%
$9.86
52-Week Price
$5.41 - $13.83
Market Capitalization
$14.9 Billion
Most Recent Dividend
$0.00
A Word Of Caution
Boston Scientific Corporation (BSX) has experienced a very significant drop in earnings and/or earnings estimates. In and of itself this drop in earnings could be an indication of greater troubles within the company.
Please take a moment to look at the RazorWire feed on the right hand side of the report to find more information regarding the company's dropoff in performance. Each time Boston Scientific Corp. is mentioned on business television recently should be displayed. This helps bring you up to date on any major issues they are facing right now.
Therefore, (and as always), check additional sources and available information regarding BSX before making an investment decision.
Ockham's Rating
Rating specific information requires Premium Access.
Buy Now or
Take the Tour.
BSX Revenue
For a long time, value investors have used the current share price relative to sales per share levels as an important valuation tool. We utilize a historical weighted average methodology that treats recent years more importantly in the calculation. When looking at BSX through this framework, we can see that our weighted average historical high and low Price to Sales per share ratios over the last 10 years are 4.71x and 2.58x respectively.
Utilizing this range we can see that BSX’s current Price to Sales per share ratio of 1.75x is significantly below its average levels historically. In fact, with a current price of $9.86, BSX is a full 53% below its average Price to Sales ratio at comparable sales levels. This is a rare occurrence and, when taken in context of the other areas of our analysis, can be a strong positive for our outlook for BSX.
BSX Cash Earnings
Price to Cash Earnings analysis is inappropriate for this company due to anticipated negative cash flows for this year. A negative cash flow presents many complications when comparing the company's current value to historically normal valuations. Clearly, when a company fails to earn a profit, it should be a concern for investors. As such, we have taken a negative view on BSX from a cash perspective. We should point out that this metric is a significant element in Ockham’s methodology for analyzing the outlook for any company.
Many young companies have come through difficult times like this before; these companies have an opportunity to grow revenue appropriately to bring them around to profitablity. However, for mature company's with a history of positive cash flow this can be much more distressing. Therefore, for BSX, our overall valutaion is now more dependent on the Price to Sales analysis, and investors should be cautious with a company with very limited, if any, positive cash earnings.
BSX Dividends
While it is not necessary to pay an attractive dividend or a dividend at all, to receive a positive rating from Ockham, we view dividends as an additionally helpful measure in determining the future potential of any company. As far as our investing methodology goes, it is not necessary to pay a dividend in order to get a favorable rating, so as for right now BSX gets a neutral rating for the dividend portion of the model. As you can see, we are not receiving historical dividend information from our data provider on BSX at this time.
The latest TV Media Discussion
“…More than 3%, 3.5% of the total but the fact today is we saw broad-based demand in some of the consumer stocks. Lennar, bed, bath & beyond, BOSTON SCIENTIFIC, and sallie mae all very, very strong on what turned out to be a very …” …more details…
“…Given elliott's track record, jpn has done investment bankment for boston sci and wants to do some more. Elliott as poimt also reunites him with sam leno the cfo at BOSTON SCIENTIFIC. These two were a team at zimmer. For more check out my blog pharmasmarket.Cnbc.Com. And you can find follow me at twitter. …” …more details…
“…But that franchise is facing increased competition. And he beat back johnson & johnson in the fight for guidin. Just this week the company on the implantable heart devices that BOSTON SCIENTIFIC got from guidant. Analysts think the study which showed the $28,000 gadgets could save the lives of heart failure patients may help reinvigorate sales growth there. Jpmorgan's med tech analyst mike …” …more details…
“…During ray elliott's tenure at zmh the stock more than doubled, up 131%, whereas during the ten-year reign of jim tobin at bsx the stock, as you see, has been cut more than in half. BOSTON SCIENTIFIC announced today that the 65-year-old tobin is stepping down. Despite the stock's performance, the press release says tobin has "helped improve the lives of millions of patients." …” …more details…
“…>> good afternoon, matt. The company that makes expensive little electronic devices to jumpstart the heart is delivering a jolt to its stock today with the announcement that its leader is leaving. Shares of BOSTON SCIENTIFIC are the biggest percentage gainer in the big cap medical device they are off of their highs of the day, right now up about 5 1/3%. Investors are apparently very …” …more details…
“…Before the closing bell sounds dow industrials right now up in the triple digits, holding on to a gain of 150. >> transports up 4%. Best day this month, transports. We're also going to be checking out BOSTON SCIENTIFIC. It's having a strong day, leading the health care index we'll be looking at what's going on with bsx when we get back. …” …more details…
“…I am beginning to think they will come back to the health care stocks now that we've seen the whites of their eyes and have clarity on health care. There BOSTON SCIENTIFIC makes another stock I will save for my "off the chart" segment because I am, indeed, a tease. Rodney in new york. Rodney! >> caller: boo-yah, jim. Thanks for taking my call. …” …more details…
“…>> well, there are three new players in this market. The largest player is medtronics. That is a company that has more leverage to it. BOSTON SCIENTIFIC and st. Jude's medical means more to their >> have these stocks already factored this in? >> we made a call last month we thought this trial was good and thought the results would be positive. …” …more details…
“…Maybe it's going down. >> I might look elsewhere. >> let's move on to the next medical device maker shares of st. Jude's and BOSTON SCIENTIFIC up 3% after a trial of a new implantable device. Let's bring in our devices analyst. …” …more details…
“…Considering issuing 3.25 million shares of common stock in an effort to raise capital. >> number two, BOSTON SCIENTIFIC. Long term study showed recipients from early stage heart failure using their …” …more details…
“…Traffic and major air carriers. They continue to drop. Ual, parent company of united down 10% on the session. After that, I thought i'd follow up with a winning stock on the day. BOSTON SCIENTIFIC, seeing good volume on the day. The company announcing some success success success with the defibrillator. …” …more details…
“…Implanted electronic device, the incident of death and need for surgery can be cut by nearly 30% and early intervention could slow down progression. BOSTON SCIENTIFIC, medtronic and st. Jude make the two in one implantable devices, a defif later and regulator for heart a multi billion dollar segment …” …more details…
“…And, lastly, heading into the president's big president conference here happening at 12:30 eastern time, traders down here watching those healthcare stocks on j & j, all -- BOSTON SCIENTIFIC in the news announcing test results on some defibrillators. Traders pointing out we're seeing mixed trading in those healthcare stocks. …” …more details…
“…Welcome back. The dow is off 21 points right now. And also, BOSTON SCIENTIFIC. This is a large clinical trial, to slow the progression of heart …” …more details…
“…Analysts believe it could reinvigorate growth which has been plagued buy a number of safety issues in recent years. So there are three stocks to of course, BOSTON SCIENTIFIC but also medtronic and and st. Jude medical, but jpmorgan med tech analysts weinstein has been telling clients stj may be the …” …more details…
“…Health care reform, comes the major study that some will argue save the americans a lot of money and lives. BOSTON SCIENTIFIC says its two in one heart device met its main goal reducing death by 29% beating the 25% benefit that researchers were shooting for …” …more details…
“…Of pressure, friedman billings ramsey saying the worst is behind the company and site almost 2 billion in fresh capital. Good for a 6% move. BOSTON SCIENTIFIC this morning, there's clinical studies saying their heart resinkynchronizization, more for heart failure than …” …more details…
“…Russia is down 23% in two weeks. The eemergencying markets index is done. Copper is down about 11%. Gasoline also down double digits keep an eye on that here's BOSTON SCIENTIFIC, I just want to note very quickly here what's going on and ubs as well. "the new york times" saying the justice department may drop its efforts to force the bank to …” …more details…
“…Boeing delaying first flight of the 787 dreamliner, we'll see what kind of impact this has on unat 10:00. >> let's foreclosure up here. BOSTON SCIENTIFIC is trading up a little bit here. They announced positive results from their heart device study. Mike huckman will have the details. …” …more details…
“…Host of safety problems that everybody's aware of. So three stocks to watch here. You're looking at them. Obviously, BOSTON SCIENTIFIC, medtronic which controls the lion's share of this device, and jpmorgan analyst has been telling clients for weeks that st. Jude may be the best way to …” …more details…
“…These results of a very big study that some are definitely going to argue could save the american health system a lot of money and could save a lot of lives at the same time. That's because BOSTON SCIENTIFIC has just released the findings of a long-anticipated clinical trial of what is essentially a 2 in 1 implantable heart device. A defibrillatoring and a cardiac resinkization for those with early heart failure. BOSTON SCIENTIFIC says this big study met it's main goal and resulted in a 29% reduction in death. It was looking to meet a threshold of 25%. So, obviously, it beat that. …” …more details…
“…Our systems are robust, reliable and are safe and effective for people who need them for whatever problems they may have. >> meantime, results of a big BOSTON SCIENTIFIC sponsored study of icds are expected any day now. Many analysts think if they're positive they could reignite sales growth. …” …more details…
“…Healthcare reforms, with insiders view to the according to public records she earned more than 2 million in past two years on corporate boards as BOSTON SCIENTIFIC and cerner and medco health solutions. Does this add up to a conflict of interest for president obama's pick? Kirsten powers. …” …more details…
“…But jpmorgan medical device analyst says st. Jude could be the biggest beneficiary of a potential turn around because icds make up a bigger portion of its bottom line. BOSTON SCIENTIFIC paid for this study but dr. Moss said they were entirely hands off. He said he stopped accepting …” …more details…
“…Term, so now it saves 1.2 years of life over an eight-year period. That's quite considerable. So this should have a positive >> however, there is another BOSTON SCIENTIFIC sponsored study that dr. Moss and analysts say could have a more significant impact on icd sales …” …more details…
“…Reimbursement numbers that were very positive for medtronics. It's one reason abbott is ramping after going down. BOSTON SCIENTIFIC, some j & j. Striker. Striker in ages. You know, i've had zimmer. These are not done because everyone was banging on these, …” …more details…
“…And blew them away on the top line. Gave good guidance and this company is about the disease prevention via population BOSTON SCIENTIFIC, I always liked this stock. Great american success story. Not as much, but did beat the earnings, 19 cents. Street was looking for 12 cents. A defibrillator and pacemaker …” …more details…
“…Boss top scientific, ibm, texas instruments. Texas instruments expected to swing to a loss. Expectations in ibm is holding steady with their earnings. BOSTON SCIENTIFIC, the am lists forecast drop of 227%. Looking forward to earnings after the bell. >> interested to see if ibm …” …more details…
“…Flatness in diprexa and the fact their revenues lost 6 full percentage points due to the dollar. So the currency really crushed the quarter for them on revenues. After the close, it's ibm, texas instruments and BOSTON SCIENTIFIC. So the earnings parade back to you guys. …” …more details…
“…Eagle, ibm international >> caller: I have fmer, first >> caller: I have eix edison, and I have bsf BOSTON SCIENTIFIC. >> let's see what we're got here, a little complicated, a little complicated. We have agnico eagle, my favorite gold stock though I like the gld. BOSTON SCIENTIFIC, my significant health care stock, one in the single digits, first merit, the controversial one, a small regional that I think is going to take over the world, not unlike first niagara the I think you'll be able to buy a …” …more details…
“…>> thank you very much, sir. >> caller: I want to give a california go laker bah bah-boo-yah. BOSTON SCIENTIFIC. What do you think? >> I want to buy bsx. I know the group has fallen hideously out of favor. I know medical devices are I think we're about to see we are out of a depression but we are still in a recession, which >> buy buy buy! >> bsx a nice comeback play. And they've also fixed the balance sheet. Nikki in maryland. Nikki. Big boo-yah, jim. …” …more details…
“…And patients can be comfortable with a decision to use them and not be worried about any safety >> so there are now four companies making them. Abbott, BOSTON SCIENTIFIC, johnson & johnson, medtronic. Separately, there were other studies present that had could trade today. …” …more details…
“…I think it's because of this it has chilli in it. >> did they get a stent from BOSTON SCIENTIFIC? >> you have to make sponsorship these days, a7} great medical >> should I try this thing? >> why not. …” …more details…
“…They're looking at consumer they're even beginning I think to come back and look at health care right now. Names like medtech, abbott, and BOSTON SCIENTIFIC, which is had its own issues, but in this kind of market these are the places they come back to, it's where the -- >> you've got so much data coming at you on your desk every day, and for a little while we …” …more details…
“…And it's bridge day in detroit. Can the auto marks make it to the starting line in time. >>> we recommend the sale of BOSTON SCIENTIFIC, almost two years ago at $18. We're changing our view down here at $8. We think it has earnings we think no one is paying it's in the strongest group in the market, which is in the medical device business. Bsx should be bought for better than expected quarter. It's speculation. Axis technologies, axys, that's unmanned cameras that see the bad guys. Use limits, please. …” …more details…
“…The worst house in a great neighborhood, which is a lot better than being the best house in the house of pain. Here's the bottom line -- how can you mend a broken heart? How about how can you mend a broken stock? BOSTON SCIENTIFIC has been a broken stock, but I don't think it's a broken company anymore. I told you to get out of it 18th. I'm telling you to get back into it at $8. I knew what I was talking about …” …more details…
“…Products in the u.S. In cardiovascular and other divisions, 12 new launches outside the u.S. Now, this is amazing, it expects 38% of the revenue from new the company is reinventing itself. Even as BOSTON SCIENTIFIC's stock has been bludgeoned, right down to the dreaded under ten zone, the company's been focused on innovation. I think it's going to recover. What about catalysts? Bsx's next-generation to be approved by the eu and launched in europe this year. The sooner this happens, the more confident the analysts who are still waiting on the fence that's a big datapoint. All this adds up to a company in …” …more details…
“…They intend to shut down 5 of its 17 plants in the next three years, eliminate 4,300 jobs. That will save them money. Again, we need that from any indebted company. Bsx is a cash machine. Think of it as an atm, generating $180 million in cash flow every month, which is much better, of course, than a sharp boeing knife in the eye, especially in this market. The company wants six nor …” …more details…
“…Billion in debt and now has $1.6 billion in cash on hand. Its next debt maturity isn't until april of 2010. I feel confident they can roll that over. Bsx has been through a restructuring process. It took a port foalfolio of 100 different investments, combing it down to about 20 by selling off non-strategic assets. In 2008, the company got $1.4 …” …more details…
“…You want one, you get it because you need it -- not elective, i'm that's not the kind of business that hurts during a recession. You get this because, well, they think you're going to die. But a lot of people have been burned believing that bsx had turned a corner. Trust me, this one has been a not not a led zeppelin or even a mariah carey heartbreaker. …” …more details…